News

Fintel reports that on August 7, 2023, EF Hutton reiterated coverage of GT Biopharma (NASDAQ:GTBP) with a Hold recommendation.

Analyst Price Forecast Suggests 1,175.00% Upside

As of August 2, 2023, the average one-year price target for GT Biopharma is 3.57. The forecasts range from a low of 2.02 to a high of $5.25. The average price target represents an increase of 1,175.00% from its latest reported closing price of 0.28.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for GT Biopharma is 0MM. The projected annual non-GAAP EPS is -0.60.

What is the Fund Sentiment?

There are 51 funds or institutions reporting positions in GT Biopharma. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to GTBP is 0.00%, a decrease of 59.16%. Total shares owned by institutions decreased in the last three months by 12.41% to 5,597K shares.

The put/call ratio of GTBP is 0.00, indicating a bullish outlook.

What are Other Shareholders Doing?

Armistice Capital holds 2,200K shares representing 5.88% ownership of the company. In it's prior filing, the firm reported owning 3,390K shares, representing a decrease of 54.09%. The firm decreased its portfolio allocation in GTBP by 66.74% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 804K shares representing 2.15% ownership of the company. No change in the last quarter.

Bank Of Montreal holds 596K shares representing 1.59% ownership of the company.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 276K shares representing 0.74% ownership of the company. No change in the last quarter.

Geode Capital Management holds 223K shares representing 0.60% ownership of the company. No change in the last quarter.

GT Biopharma Background Information
(This description is provided by the company.)

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.

Additional reading:

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.